Physician profile
Xiaoyan Wang
NPI 1912110255
$4,177.39
in general payments reported to CMS, 2019-2025
37 companies · $694 in 2025
The $694 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $157 · 2021: $31.85 · 2022: $877 · 2023: $838 · 2024: $1,121 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,098 · Long Term Medical Supply Or Device Loan: $299 · Education: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,097.98 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $254.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $414.02 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $343.83 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $269.32 | 2022-2025 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $259.82 | 2022-2024 | Fruzaqla |
| Astrazeneca Pharmaceuticals LP | $243.21 | 2019-2025 | Enhertu, Imfinzi |
| Celgene Corporation | $240.34 | 2019-2024 | Pomalyst |
| Merck Sharp & Dohme LLC | $229.31 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Pharmacyclics LLC, An Abbvie Company | $225.50 | 2019-2023 | Imbruvica |
| Janssen Biotech, INC. | $220.15 | 2020-2025 | Darzalex, Talvey, Tecvayli |
| Beigene USA, INC. | $202.12 | 2023 | Brukinsa |
| Eisai INC. | $163.45 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $153.75 | 2022-2025 | Libtayo |
| Abbott Laboratories | $112.01 | 2025 | Esprit |
| Lilly USA, LLC | $95.73 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Taiho Oncology, INC. | $92.67 | 2022-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $91.57 | 2019-2024 | Phesgo |
| Gilead Sciences, INC. | $91.47 | 2024-2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $61.10 | 2019-2024 | Tavalisse, Rezlidhia |
| Alexion Pharmaceuticals, INC. | $58.53 | 2024 | Ultomiris |
| Astellas Pharma US INC | $50.58 | 2024-2025 | Padcev |
| Jazz Pharmaceuticals INC. | $50.00 | 2019 | |
| Daiichi Sankyo INC. | $48.20 | 2024 | Enhertu |
| Emd Serono, INC. | $47.36 | 2019-2020 | |
| Caris Mpi, INC. | $42.92 | 2025 | Mi Cancer Seek |
| Organon LLC | $40.79 | 2022-2024 | |
| Tempus Ai, INC | $38.09 | 2025 | Xt Cdx |
| Boston Scientific Corporation | $36.05 | 2022 | |
| Pharmaessentia USA Corporation | $33.08 | 2024 | Besremi |
| Genmab U.S., INC. | $31.76 | 2025 | Epkinly |
| Abbvie INC. | $26.64 | 2024 | |
| Pharmacosmos Therapeutics INC. | $25.61 | 2025 | Monoferric |
| Kite Pharma, INC. | $25.59 | 2025 | Yescarta |
| Genzyme Corporation | $24.35 | 2022 | |
| Mirati Therapeutics, INC. | $24.31 | 2024 | Krazati |
| Sobi, INC | $22.27 | 2025 | |
| Acrotech Biopharma INC. | $21.65 | 2024 | Beleodaq |
| Spectrum Pharmaceuticals INC. | $20.24 | 2024 | Rolvedon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaoyan Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.